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Abstract In patients with nonvalvular atrial fibrillation, oral
anticoagulation with the vitamin K antagonists acenocoumarol,
phenprocoumon and warfarin reduces the risk of stroke by
more than 60 %, whereas single or double antiplatelet therapy
is much less effective and sometimes associated with a similar
bleeding risk as vitamin K antagonists. Besides bleeding, and
intracranial haemorrhage in particular, INR monitoring re-
mains the largest drawback of vitamin K antagonists. In the
last decade oral agents have been developed that directly block
the activity of thrombin (factor IIa), as well as drugs that
directly inhibit activated factor X (Xa), which is the first
compound in the final common pathway to the activation of
thrombin. These agents have been approved for stroke preven-
tion in atrial fibrillation and are now reimbursed under a
national guideline for their safe use. They have advantages in
that they do not need monitoring and have a fast onset and
offset of action, but lack an established specific antidote. This
survey addresses the role of modern anticoagulation for stroke
prevention in atrial fibrillation.
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The yearly incidence of stroke in patients with atrial fibrilla-
tion is about 5 % [1], which is 5 times higher than in compa-
rable populations in sinus rhythm. The stroke risk largely
depends on the underlying heart disease. In ‘lone’ atrial fibril-
lation (absence of heart disease) the stroke risk is only 0.5 %
per year [2], whereas in atrial fibrillation associated with
rheumatic valvular heart disease, such as mitral valve stenosis,
it is very high. Also in other heart diseases when atrial fibril-
lation is absent, such as congestive heart failure, the stroke risk
is elevated [3].
The classical anticoagulants
The coagulation cascade is a complex system, which can be
activated by an intrinsic pathway (blood stasis and contact
activation) or an extrinsic pathway (exposed tissue after vas-
cular damage). The final common pathway from these two
potential stimuli starts with the activation of plasma factor X
into activated factor Xa (Fig. 1). Through activation of factor
V, factor II (prothrombin) is activated to thrombin, the aggres-
sive compound splitting fibrinogen into fibrin, which is the
matrix of blood clots. The coagulation system is a real cas-
cade. One molecule of factor Xa induces the formation of 50
thrombin molecules. Factor Xa and thrombin are counteracted
by the naturally occurring antithrombin-III.
Until recently, the only available oral anticoagulants were
the coumarin derivatives. These compounds block the vitamin
K dependent liver production of the plasma coagulation fac-
tors II, VII, IX and X. They are usually called vitamin K
antagonists and have a relatively narrow therapeutic window,
which is due to dose response, food and genetic variation.
Therefore, vitamin K antagonists require close monitoring:
overdosing may result in life-threatening bleeding and
underdosing in inefficacy. An international and uniform labo-
ratory standard of the intensity of anticoagulation has been
introduced: the International Normalised Ratio (INR) replac-
ing the non-standardised prothrombin time and Quick tests.
Nevertheless, monitoring remains cumbersome and less than
two-thirds of patients on chronic vitamin K antagonist therapy
are within the therapeutic window.
Warfarin therapy is the cornerstone in the prevention of
thromboembolism in patients with atrial fibrillation. Stroke in
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patients with persistent or permanent non-valvular atrial fibril-
lation can be reduced by 67 % by the use of oral anticoagulants
[4]. Severe bleeding with warfarin is seen in 1 out of 100
patients per year, which is double the risk of stroke in lone
atrial fibrillation. Therefore, anticoagulation is only indicated in
atrial fibrillation patients with a stroke risk that exceeds the risk
of severe bleeding. Risk stratification for stroke in atrial fibril-
lation is now widely accepted with the CHA2DS2VASc score
[5], where patients with a score of 1 and higher are candidates
for oral anticoagulation (Table 1). In atrial fibrillation also the
presence of aortic plaque is associated with an elevated stroke
risk [6]. The optimal target INR for patients on vitamin K
antagonists is between 2.0 and 3.0 [7]. In the Netherlands a
higher target INR is advised, but this has never been confirmed
to be more effective and/or safer in atrial fibrillation than the
internationally accepted target range. In selected patients with
atrial fibrillation, vitamin K antagonists have to be interrupted
for surgical procedures, but in those undergoing pulmonary
vein isolation they can be continued [8].
Yet, the use of vitamin K antagonists is associated with the
risk of severe and even fatal bleeding. Many physicians are
reluctant to prescribe warfarin to the elderly patient with atrial
fibrillation because of the risk of bleeding, and many are
convinced that aspirin is a wise and acceptable alternative.
However, there are now reassuring comparative data in the
very elderly (over 75 years) showing superiority of warfarin
over aspirin with equal bleeding risk for both therapies [9].
This is one of the reasons antiplatelet therapy is now discour-
aged in stroke prevention in the European guidelines [5].
The new oral anticoagulants
In the past decade several oral direct inhibitors of thrombin
and of factor Xa have been developed (Table 2). They proved
to be specific antagonists and show a dose-efficacy relation-
ship. A major advantage is that there does not seem to be any
drug tolerance and food interaction, and monitoring is not
needed with these agents. They have a fast onset of activity
and a relatively short duration of action, which in case of
bleeding or planned surgery is another advantage over vitamin
K antagonists. On the other hand, some agents need twice
daily dosing and the fast offset of action may be problematic
in case of poor compliance, e.g. when the patient does not take
2 or 3 doses in sequence. This disadvantage is not seen with
warfarin, which has a very slow offset of action. Furthermore,
an antidote algorithm for the novel oral anticoagulants has not
been developed yet, while this is well established for warfarin.
Fig. 1 Simplified diagram
showing the coagulation cascade
Table 1 CHA2DS2VASc score points for prediction of stroke in atrial
fibrillation [5]
Risk factor Points
Age 65–75 years 1
Age over 75 years 2
Female gender 1
Coronary or peripheral artery disease 1
Previous stroke 2
Hypertension 1
Symptoms or signs of left ventricular dysfunction 1
Diabetes mellitus 1
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The advantages and disadvantages of the novel oral anti-
coagulants relative to vitamin K antagonists are summarised
in Table 3.
The trials and registries
In atrial fibrillation the direct oral thrombin (factor IIa) inhib-
itor ximelagatran is as effective as warfarin and reduces major
bleeding [10, 11], but the drug is associated with liver toxicity,
which withholds its approval and further marketing. Another
direct oral thrombin blocker, dabigatran, has been evaluated in
comparison with warfarin in the huge phase III RE-LY trial in
atrial fibrillation [12]. Finally, oral direct factor Xa blockers
have become available and are effective in the prevention and
treatment of deep vein thrombosis and pulmonary embolism
[13–18]. Rivaroxaban, apixaban and edoxaban have been
tested for stroke prevention in atrial fibrillation (Table 4)
[19, 20]. Except for edoxaban, where results will be available
shortly, they show better or equal efficacy compared with
warfarin at no excess bleeding [12, 19, 20]. As shown in
Table 4, the trials differ in design in that RE-LY is open label
and the other double blind, by which INR is measured at the
point of care and sham INRs are computer-generated for the
patients randomised to the new agent. Double-blind controlled
trials are the highest standard of quality in evidence-based
medicine and also in the case of INR monitored trials blinding
is feasible and successful [11]. Open-label studies have the
serious shortcoming of treatment bias. In case of bleedingwith
open-label warfarin, physicians will react differently than with
bleeding with a drug that could be either an experimental
short-acting new oral anticoagulant or warfarin. Therefore,
the design of RE-LY makes its outcome on softer endpoints
doubtful. A good example of this is the differential results of
the studies where ximelagatranwas comparedwith warfarin in
stroke prevention for atrial fibrillation. SPORTIF-III was an
open-label trial and stroke prevention tended to be better with
ximelagatran than with warfarin [10], but in SPORTIF-V with
its double-blind design it was the other way around [11]. The
ximelagatran arms of both trials had an almost identical out-
come making both studies highly comparable in baseline
features. Although complex to perform, trials of the new oral
anticoagulants had to be double-blind in design. The trials in
evidence-based medicine we use nowadays were tested
double-blind in the 1990s, such as those on beta blockers,
aspirin, statins and ACE inhibitors.
By design, the trials included both warfarin-experienced
and warfarin-naive patients and by stratification the results
Table 3 Advantages and disadvantages of the new oral anticoagulants relative to warfarin
Class Advantages Disadvantages
Oral direct IIa/Xa blockers More effective against thromboembolism than VKA No monitoring in case of bleeding or urgent surgery
Fast onset of action Not applicable in severe renal failure (CrCl <30 ml/min)
Fast offset of action (in case of bleeding/surgery) Not applicable in carriers of artificial heart valves
Better safety, especially less intracranial bleeding than
VKA
Short duration of action (thrombosis risk with poor compliance
Ease (no monitoring) Antidote strategy not established
Some agents have interaction with anti-arrhythmic agents
Vitamin K antagonists Therapeutic window established Monitoring of INR
Antidote algorithm established Drug interaction with many agents
Long duration of action Food interaction
(low thrombosis risk with poor compliance) Slow onset of action
High bleeding risk, intracranial bleeding in particular
VKA vitamin K antagonists, IIa activated factor II (thrombin), Xa activated factor X
Table 2 The new oral
anticoagulants
IIa activated factor II (thrombin),
Xa activated factor X, T ½ (h)
plasma half-life (hours), b .i .d .
twice daily, qd once daily
a not yet approved
Class Name T ½ (h) Dosing Excretion
Anti-IIa (antithrombin) Dabigatran (PradaxaR) 7–9 b.i.d. 80 % kidney, 20 % liver
Anti-Xa Apixaban (EliquisR) 8–15 b.i.d. 21 % kidney, 78 % liver
Rivaroxaban (XareltoR) 9–12 qd 33 % kidney, 66 % liver
Edoxaban (LixianaR)a 8–10 qd 35 % kidney, 65 % liver
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on both efficacy and bleeding proved similar in the three
trials. This suggests that newcomers with atrial fibrillation
benefit from the new drugs as well as those who have been
switched from warfarin to the new strategy. However, these
are post-hoc analyses, which have been heavily criticised in
this kind of trial in atrial fibrillation, such as the ACTIVE-W
study [21].
Finally, until recently there were no data on the long-term
safety and efficacy of the new drugs. But, recently, a more
than 4-year follow-up study of about half of the patients on
both doses of dabigatran in the RE-LY trial, who continued the
drug, was published [22]. It showed acceptable gastrointesti-
nal bleeding and stroke data, but this was a highly selected
population without a control group, which does not defini-
tively confirm dabigatran’s safety [23]. On the other hand, a
mini-sentinel analysis by the Food and Drug Administration
in the US also showed a favourable safety profile of
dabigatran when compared with warfarin [24]. In five trials
of controlled studies with dabigatran in the prevention and
treatment of thrombosis, fatal bleeding was lower than with
warfarin [25], which confirmed another meta-analysis of all
new agents versus warfarin [26]. Although there is still no
effective specific antidote for the new drugs, these data make
the development of such an antidote less urgent. Unspecific
regimens such as prothrombin concentrate complex (CofactR)
seem to be a reasonable alternative for the inactivation of the
Xa blocker rivaroxaban, but not the IIa blocker dabigatran, but
this has only been tested in young healthy volunteers [27].
Introduction of the new oral anticoagulants
It took quite a while in the Netherlands before the new agents
became eligible for reimbursement after approval for their use
in atrial fibrillation [28], when compared with other regions in
the EU and in the rest of the world. The reimbursement will
not affect the cardiology budgets. The government produced a
report about appropriate use [29] and the national society of
medical specialists published a broadly based guideline for
safe utilisation [30] of the new oral anticoagulants for the
various indications. Not general practitioners, but only medi-
cal specialists such as cardiologists, orthopaedic surgeons,
neurologists and internists are allowed to prescribe the agents.
Finally, major and life-threatening bleeding must be reported
according to the Lareb Intensive Monitoring Program (www.
lareb.nl). The checklist derived from the national guideline is
summarised in Table 5.
Recently, the European Heart Rhythm Association pub-
lished a very useful and more extensive practical guide on
the use of the new agents in atrial fibrillation [31]. In this paper
also drug interactions are described more in detail as well as
what to dowith cardioversion and with patients suffering from
Table 4 Phase III trials with new oral anticoagulants in atrial fibrillation
Class Name Comparator Design n Trial
Anti-IIa (antithrombin) Dabigatran Warfarin (clinic) Open 18,133 RE-LY [12]
Anti-Xa Apixaban Warfarin (point of care) Double-blind 14,264 ROCKET-AF [19]
Rivaroxaban Warfarin (point of care) Double-blind 18,201 ARISTOTLEF [20]
Edoxaban Warfarin (point of care) Double-blind > 21,000 ENGAGE AF TIMI-48a
IIa activated factor II (thrombin), Xa activated factor X, n number of patients
a to be presented late 2013
Table 5 Checklist for safe use of
the new oral anticoagulants [26]
VKA vitamin K antagonist, INR
International Normalised Ratio,
NOAC new oral anticoagulant
Organisation A local protocol for handling of bleeding and/or surgery must be written
Prescription Fill out the doctor’s statement and explain transition if the patient is on VKA
Renal function Creatinine clearance should be more than 30 ml/min
Transition Stop VKA and wait for the INR to be <2.0 before starting NOAC
Elective major procedure Stop NOAC 24–48 h ahead according to renal function, no bridging
Elective minor procedure Consider NOAC continuation
Minor bleeding Consider NOAC continuation
Moderate bleeding Skip one NOAC dose and perform haemostasis
Major bleeding Stop NOAC, perform haemostasis and consider CofactR and/or CyclokapronR
Life-threatening bleeding All of the above and consider NovosevenR
Reporting of bleeding Severe bleeding must be reported to Lareb Monitoring Program (www.lareb.nl)
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comorbidities: coronary artery disease treated with or without
revascularisation, acute stroke and cancer.
Conclusion
From the current trials it has become clear that oral direct
inhibition of the major haemostatic proteins factor IIa or factor
Xa is at least as effective as warfarin in stroke prevention of
atrial fibrillation with a safety profile which is far more
favourable than warfarin, especially where intracranial bleed-
ing is concerned. The lack of monitoring will be the major
reason for many physicians to switch fromwarfarin to the new
agents and to put newcomers with atrial fibrillation without
anticoagulants on them right away.
The current absence of an antidote has not led to cata-
strophic bleeding in the trials and the recent registries. The
only significant clinical drawback is that the new agents
cannot be used in patients with severe renal failure and in
those with artificial heart valves.
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